$PMD · placeholder governance primitive. No mainnet supply.
This page exists so anyone evaluating Peptide MD can see the eventual token shape, the allocation, the jurisdictional posture, and the risks. There is no token sale. There is no presale. There is no whitelist. $PMD has no public mainnet supply, no liquidity, and no listing. Any communication suggesting otherwise is not us.
Forward-looking, not a solicitation
Nothing on this page is an offer to sell or a solicitation of an offer to buy any security or digital asset, in any jurisdiction where such an offer or solicitation would be unlawful. The figures, percentages, and structure described are subject to change pending regulatory review. Forward-looking statements are not promises. Tokens, if ever issued, may carry total loss risk. Read Risk factors in full.
Indicative allocation (pre-issuance · 100% accounted)
- Cohort cooperative reserve25%Distributed to OEA-revealed cohorts pro-rata to participant count and outcome quality.
- Researcher / IPNFT mint pool20%Vested over 4 years against indexed peptides; cliff at 12 months from IPNFT mint.
- CRO / supplier incentive pool12%Reputation-weighted; emits on auction completion under successful OEA reveal.
- Treasury (operations + audits)18%Multi-sig held by founders + council seats; quarterly burn rate reported on /changelog.
- Council compensation pool6%Stipends for the six council seats; any unused portion returns to treasury.
- Liquidity provisioning8%Reserved for permanent on-chain liquidity at TGE; locked for 24 months.
- Founders + early team11%4-year linear vest, 12-month cliff. Subject to council clawback for material breach.
Jurisdictional posture
Eight regions in scope. None of these constitute legal opinions; they are our public posture pending each region's review. We will not sell, promote, or list $PMD into a region until the posture turns green for that region.
| Region | Likely classification | Our posture |
|---|---|---|
| United States | Indeterminate · likely investment contract under Howey factors as currently structured | no participation No US-person sale. No Reg D / Reg A filing as of this disclosure. Howey analysis published with v1 token paper. |
| European Union (MiCA) | Likely Asset-referenced or Utility - pending classification opinion | review MiCA white paper requirements acknowledged; CASP partner being scoped before any public sale. |
| United Kingdom (FCA) | Likely unregulated token; financial promotion regime applies to any UK-targeted communication | review No UK-targeted promotion until s.21 FSMA approver appointed. |
| Switzerland (FINMA) | Likely Utility token under FINMA ICO guidelines | review Pre-launch no-action enquiry intended before TGE; outcome will be published. |
| Singapore (MAS) | Likely Digital Payment Token under PSA + Utility characteristics | review No retail offer; consultation with MAS sandbox unit prior to TGE. |
| Japan (FSA / JVCEA) | Indeterminate; likely Type 1 Crypto-Asset under PSA depending on issuance form | no participation No JPY-pair listing intended for v1. |
| Canada (CSA) | Likely security token under SN 46-308; subject to prospectus exemption analysis | no participation No CA-resident sale until exemption strategy published. |
| Australia (ASIC) | Likely financial product under INFO 225 | review AFSL pathway under review; no AU-resident participation until completed. |
Risk factors
Any token, if issued, may lose all value. There is no protected principal, no insured custody, no government-backed guarantee.
Classification varies by jurisdiction and may change. A sale in one region does not legitimize a sale elsewhere.
Audits reduce but do not eliminate exploitation risk. Cohort treasuries and royalty cascades may be drained or frozen by a bug.
Indexed peptides and protocols may not produce the outcomes their posteriors predict. The Living Outcome Oracle is calibrated to past data only.
Several protocol surfaces require council sign-off. Until seats are filled, those surfaces operate under a public interim posture and may produce slower decisions.
CROs, suppliers, and cohort hosts may default on commitments. Royalty cascade payouts depend on real-world cash flows, not on-chain alone.
Any token migration, fork, or chain re-deployment may cause partial losses. We commit to publishing migration plans in advance on /changelog.
Token receipt, vesting events, royalty distributions, and IPNFT secondary sales may be taxable events in your jurisdiction. Consult a tax professional.